Particle Sciences and Pernix Therapeutics have entered into an agreement to develop a new topical dermatology product for the pediatric market.
Subscribe to our email newsletter
Particle Sciences, a provider of drug development services, focuses on emulsions, gels, micro and nano-particulates, drug/device combination products and potent compounds across all dosage forms.
Particle Sciences CEO Mark Mitchnick said the company is applying advanced drug delivery and formulation technologies to an established pediatric product category.
Pernix President and CEO Cooper Collins said the company is working with Particle Sciences for the product candidate, which may be another opportunity to further expand its pediatric product line.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.